Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
This trial focuses on adults with certain immune problems caused by Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma. Researchers are studying whether receiving Gamunex-C through an intravenous infusion every four weeks, along with usual medical care, reduces serious infections over one year. The study is an open-label, multi-center, single-arm trial led by Grifols Biologicals, LLC. Participants will receive 13 doses of Gamunex-C at 500 mgkg via IV infusion starting on Day 1 through Week 48, given once every four weeks. This treatment phase lasts one year, and all participants receive the investigational drug without a comparison group or placebo. The study evaluates the drugs effects alongside standard medical treatment. During the study, participants will be monitored for serious bacterial infections and other related outcomes for the duration of treatment and up to 28 days after the last dose. Assessments include tracking infection rates, antibiotic use, hospitalizations, and safety measures. The total participation time covers the one-year treatment period plus the short post-treatment observation phase.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.
Actively Recruiting
Researchers are studying adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This trial aims to compare the levels of drug exposure following treatment with tislelizumab given as a subcutaneous injection versus an intravenous infusion as first-line therapy. The study includes approximately 351 participants and is sponsored by BeOne Medicines. Participants are randomly assigned to one of two groups one group receives tislelizumab 300 mg as a subcutaneous injection on Day 1 of each 21-day cycle, followed by chemotherapy chosen individually the other group receives tislelizumab 200 mg as an intravenous infusion on Day 1 of each 21-day cycle, also followed by individualized chemotherapy. Chemotherapy drugs may include cisplatin, leucovorin, 5-fluorouracil, oxaliplatin, or capecitabine. The study is divided into a screening period, a treatment period, and a follow-up period. Throughout the study, participants will be monitored for drug levels, tumor response, survival, and adverse events for up to two years. Assessments include measuring the steady state trough concentration and area under the concentration-time curve of tislelizumab, as well as evaluating tumor response rates and disease control. Safety and antibody responses will also be tracked. Participants will undergo regular visits to collect medical data and ensure adherence to the treatment plan during the study period.
Actively Recruiting
Researchers are studying AMG 436 in participants with metastatic or locally advanced solid tumors that have microsatellite instability-high MSI-H or mismatch repair deficiency dMMR. The trial aims to evaluate the safety profile of AMG 436 and to identify the maximum tolerated dose or recommended dose when given alone or combined with other anti-cancer treatments. This Phase 11b study focuses on understanding how AMG 436 works in these specific tumor types. Participants will receive AMG 436 either as a single agent or combined with chemotherapy in various dose escalation and expansion phases. Some participants in the United States will receive AMG 436 under both fasted and fed conditions to assess potential food effects. The study includes multiple parts monotherapy dose escalation, combination dose escalation, monotherapy dose expansion and optimization, and combination dose expansions with chemotherapy. During the trial, participants will undergo regular safety and treatment monitoring for up to five years, including the assessment of dose-limiting toxicities and treatment-emergent adverse events. Researchers will also measure blood levels of AMG 436, tumor response according to standardized criteria, and other pharmacokinetic and pharmacodynamic markers. Follow-up evaluations will continue to monitor overall survival, disease progression, and treatment response duration.
Actively Recruiting
Researchers are evaluating the effectiveness of AZD2265 compared to standard treatments in men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study aims to show whether AZD2265 can improve radiographic progression-free survival and overall survival. This phase III trial involves about 670 adult male participants and is sponsored by AstraZeneca. Participants will be randomly assigned to receive either AZD2265 or a standard care treatment chosen by the investigator, which may include cabazitaxel, androgen receptor pathway inhibitors ARPI, or radium-223. Treatments will continue until the disease progresses, unacceptable side effects occur, or other reasons for stopping arise. Tumor scans will continue after treatment ends until confirmed progression or death. Throughout the study, participants will be monitored with imaging scans and laboratory tests to assess disease progression and response to treatment. Researchers will track multiple outcomes such as progression-free survival, PSA reductions, response rates, and symptomatic skeletal events for up to approximately 33 months. Safety and scientific integrity will be overseen by an independent committee, and participants will be followed for survival until the studys completion.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
1-10 of 16
1